- Home
- KOD vs NVCT Comparison
KOD vs NVCT Comparison
Compare KOD & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | NVCT |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 220.0M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KOD | NVCT |
|---|---|---|
| Price | $40.15 | $7.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $35.43 | $13.50 |
| AVG Volume (30 Days) | ★ 1.5M | 52.1K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $5.55 |
| 52 Week High | $45.60 | $11.52 |
Technical Indicators
Market Signals| Indicator | KOD | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 67.83 | 34.64 |
| Support Level | $21.82 | $7.23 |
| Resistance Level | N/A | $8.46 |
| Average True Range (ATR) | 3.46 | 0.40 |
| MACD | 1.97 | -0.10 |
| Stochastic Oscillator | 79.80 | 18.35 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.